Design and analysis considerations in the Ebola-Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak

Clinical Trials

Volumn 13, Issue 1, 2016, Pages 13-21

  Edwards, Tansy ^a   Semple, Malcolm G ^b   De Weggheleire, Anja ^c   Claeys, Yves ^c   De Crop, Maaike ^c   Menten, Joris ^c   Ravinetto, Raffaella ^c   Temmerman, Sarah ^c   Lynen, Lutgarde ^c   Bah, Elhadj Ibrahima ^d   Smith, Peter G ^a   Van Griensven, Johan ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d Service des Maladies Infectieuses et Tropicales de l Hôpital National Donka   (Guinea)

Author keywords

convalescent plasma; Ebola; Guinea; trial design

Indexed keywords

ARTICLE; BLOOD DONOR; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENT PLASMA TRANSFUSION; DATA COLLECTION METHOD; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; GUINEA; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SELECTION; PLASMA TRANSFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SELECTION BIAS; STUDY DESIGN; SUPPORTIVE CARE; SURVIVAL; SYMPTOM; TIME TO TREATMENT; VIRUS LOAD; BLOOD COMPONENT THERAPY; CLINICAL PROTOCOL; CONVALESCENCE; HEMORRHAGIC FEVER, EBOLA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PLASMA; PROCEDURES;

BLOOD COMPONENT TRANSFUSION; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CONVALESCENCE; DISEASE OUTBREAKS; GUINEA; HEMORRHAGIC FEVER, EBOLA; HUMANS; INTENTION TO TREAT ANALYSIS; PLASMA; RESEARCH DESIGN;

EID: 84957595183     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515621056     Document Type: Article

References (20)

1. Casadevall A, Dadachova E, Pirofski LA., Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2: 695-703.
2. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 80-90.
3. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999; 179: S18-S23.
4. Gulland A., First Ebola treatment is approved by WHO. BMJ 2014; 349: g5539.
5. Maurice J., WHO meeting chooses untried interventions to defeat Ebola. Lancet 2014; 384: e45-e46.
6. Gutfraind A, Meyers LA., Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia. J Infect Dis 2015; 211: 1262-1267.
7. Colebunders RL, Cannon RO., Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis 2015; 211: 1208-1210.
8. WHO Ebola Response Team. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371: 1481-1495.
9. Delamou A, Beavogui AH, Kondé MK, et al. Ebola: better protection needed for Guinean health-care workers. Lancet 2015; 385: 503-504.
10. World Health Organization (WHO). Ebola response roadmap update, http://apps.who.int/iris/bitstream/10665/135029/1/roadmapupdate26sept14-eng.pdf?ua=1 (2014,. accessed 11 November 2015).
11. World Health Organization. Ethical issues related to study design for trials on therapeutics for Ebola Virus Disease. In: WHO ethics working group meeting (summary of discussion), 20-21 October 2014, http://apps.who.int/iris/bitstream/10665/137509/1/WHO-HIS-KER-GHE-14.2-eng.pdf (. accessed 5 November 2015).
12. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim Guidance for National Health Authorities and Blood Transfusion Services, http://apps.who.int/iris/bitstream/10665/135591/1/WHO-HIS-SDS-2014.8-eng.pdf?ua=1 (2014,. accessed 5 November 2015).
13. Bannister-Tyrrell M, Gryseels C, Delamou A, et al. Blood as medicine: social meanings of blood and the success of Ebola trials. Lancet 2015; 385: 420.
14. Van Griensven J, De Weiggheleire A, Delamou A, et al. The use of Ebola convalescent plasma to treat Ebola virus disease in resource constrained settings: a perspective from the field. Clin Infect Dis. Epub ahead of print 10 2015. DOI: 10.1093/cid/civ680.
15. Grietens KP, Ribera JM, Erhart A, et al. Doctors and vampires in Sub-Saharan Africa: ethical challenges in clinical trial research. Am J Trop Med Hyg 2014; 91: 213-215.
16. Adebamowo C, Bah-Sow O, Binka F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014; 384: 1423-1424.
17. Proschan MA, Dodd LE, Price D,. Statistical considerations for a trial of Ebola virus disease therapeutics. Clin Trials 2016; 13: 39-48.
18. Claeys Y, Custers A, Michiels M, et al. Data collection in a high-risk infectious zone: challenges and lessons learned in an Ebola clinical trial in Conakry, Guinea. In: Abstracts of the 9th European congress on tropical medicine and international health, Basel, 6-10 September 2015 (also published in Trop Med Int Health 2015; 20 (Suppl 1): 1-441; Abstract no. O.5.6.2.003, p. 135).
19. Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis 2015; 15: 1292-1299.
20. Schieffelin JS, Jacob ST., Raising the standard for clinical care of patients with Ebola virus disease. Lancet Infect Dis 2015; 15: 1247-1248.